Results 11 to 20 of about 6,304,439 (300)

CANCER OF THE BREAST [PDF]

Journal of the American Medical Association, 1909
ABSTRACT The treatment of cancer of the breast still demands the most thorough excision possible. The use, in operable cases, of x-rays, toxins, yeasts and ferments, radium and similar methods, is, in my opinion, wholly unjustifiable. There is little if any encouragement that methods will soon be found of sufficient merit to replace the knife.
  +7 more sources

Pembrolizumab for Early Triple-Negative Breast Cancer.

New England Journal of Medicine, 2020
BACKGROUND Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer.
P. Schmid, J. Cortés, L. Pusztai, H. McArthur, S. Kümmel, J. Bergh, C. Denkert, Yeon-Hee Park, R. Hui, N. Harbeck, M. Takahashi, T. Foukakis, P. Fasching, F. Cardoso, M. Untch, L. Jia, V. Karantza, J. Zhao, G. Aktan, R. Dent, J. O’Shaughnessy   +20 more
semanticscholar   +1 more source

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Ca, 2021
This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer.
H. Sung, J. Ferlay, R. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray   +6 more
semanticscholar   +1 more source

Understanding breast cancer as a global health concern

British Journal of Radiology, 2021
Breast cancer is now the most commonly diagnosed cancer in the world. The most recent global cancer burden figures estimate that there were 2.26 million incident breast cancer cases in 2020 and the disease is the leading cause of cancer mortality in ...
L. Wilkinson, T. Gathani
semanticscholar   +1 more source

Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer (2024 edition) [PDF]

Zhongguo aizheng zazhi
In China, 60% of breast cancer patients were premenopausal women at the time of diagnosis. Compared with postmenopausal women, premenopausal women have strong ovarian function and secrete estrogen to promote breast cancer growth.
China Anti-Cancer Association Committee of Breast Cancer Society,
doaj   +2 more sources

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2022
The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive
W. Gradishar, M. Moran, J. Abraham, R. Aft, D. Agnese, K. Allison, B. Anderson, H. Burstein, H. Chew, C. Dang, A. Elias, S. Giordano, M. Goetz, L. Goldstein, S. Hurvitz, S. Isakoff, R. Jankowitz, S. Javid, J. Krishnamurthy, M. Leitch, J. Lyons, J. Mortimer, Sameer A. Patel, L. Pierce, L. Rosenberger, H. Rugo, Amy M. Sitapati, K. Smith, Mary Lou Smith, H. Soliman, E. Stringer-Reasor, M. Telli, J. Ward, K. Wisinski, Jessica S. Young, J. Burns, Rashmi Kumar   +36 more
semanticscholar   +1 more source

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

New England Journal of Medicine, 2021
Copyright © 2021 Massachusetts Medical Society. BACKGROUND Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell ...
A. Bardia, S. Hurvitz, S. Tolaney, D. Loirat, K. Punie, Mafalda Oliveira, A. Brufsky, S. Sardesai, K. Kalinsky, A. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortés, J. O’Shaughnessy, V. Diéras, C. Ferrario, P. Schmid, L. Carey, L. Gianni, M. Piccart, S. Loibl, D. Goldenberg, Q. Hong, M. Olivo, L. Itri, H. Rugo   +29 more
semanticscholar   +1 more source

Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities

Cell Discovery, 2023
Germline-somatic mutation interactions are universal and associated with tumorigenesis, but their role in breast cancer, especially in non-Caucasians, remains poorly characterized. We performed large-scale prospective targeted sequencing of matched tumor-
Chao Chen, Cai-Jin Lin, Yu-Chen Pei, Ding Ma, Li Liao, Si-Yuan Li, Lei Fan, Gen-Hong Di, Song-Yang Wu, Xi-Yu Liu, Yun-Jin Wang, Qi Hong, Guo-Liang Zhang, Lin-Lin Xu, Bei-Bei Li, Wei Huang, Jin-Xiu Shi, Yi-Zhou Jiang, Xin Hu, Zhi-Ming Shao   +19 more
doaj   +1 more source

Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis

BMC Cancer, 2021
Background Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients.
Dechuang Jiao, Jingyang Zhang, Jiujun Zhu, Xuhui Guo, Yue Yang, Hui Xiao, Zhenzhen Liu   +6 more
doaj   +1 more source

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.

The Journal of the National Comprehensive Cancer Network, 2023
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly.
W. Gradishar, M. Moran, J. Abraham, V. Abramson, R. Aft, D. Agnese, K. Allison, B. Anderson, H. Burstein, H. Chew, C. Dang, A. Elias, S. Giordano, M. Goetz, L. Goldstein, S. Hurvitz, R. Jankowitz, S. Javid, J. Krishnamurthy, A. Leitch, J. Lyons, J. Mortimer, Sameer A. Patel, L. Pierce, L. Rosenberger, H. Rugo, B. Schneider, Mary Lou Smith, H. Soliman, E. Stringer-Reasor, M. Telli, Mei-zhi Wei, K. Wisinski, Jessica S. Young, K. Yeung, M. Dwyer, Rashmi Kumar   +36 more
semanticscholar   +1 more source